[Update atrial fibrillation: the 2020 ESC guidelines and recent data on early rhythm control]

Area of Science:

• Cardiology
• Internal Medicine

Background:

• Atrial fibrillation (AF) poses a significant health burden, with a high risk of cardiovascular events despite current management strategies.
• European Society of Cardiology guidelines advocate an integrative therapy approach, including diagnosis and treatment algorithms like 'CC to ABC'.
• Stroke prevention remains paramount, with direct oral anticoagulants based on the CHA2DS2-VASc score being central.

Purpose of the Study:

• To evaluate the impact of early rhythm control therapy on cardiovascular outcomes in patients with atrial fibrillation.
• To assess the benefits of initiating rhythm control strategies, such as antiarrhythmic drugs or catheter ablation, early in the AF management pathway.

Main Methods:

• The study analyzed data from the randomized, prospective EAST-AFNET 4 trial.
• Participants received guideline-based AF management, with an intervention group receiving early rhythm control therapy.

Main Results:

• Early rhythm control therapy, in addition to standard AF management, led to a significant reduction in cardiovascular mortality.
• The incidence of stroke was also reduced in patients receiving early rhythm control therapy.
• The EAST-AFNET 4 trial demonstrated the safety and potential positive effects of early rhythm control interventions.

Conclusions:

• Early rhythm control therapy should be considered for all atrial fibrillation patients within the first few months of diagnosis.
• Comprehensive AF management should include addressing comorbidities and risk factors like hypertension and diabetes.
• Integrating early rhythm control strategies can improve prognosis and reduce the burden of cardiovascular events in AF patients.